Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Michail,Ignatiadis

第一单位： Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

作者： Michail,Ignatiadis ^[1] ; Dimitrios,Zardavas ^[2] ; Marc,Lemort ^[3] ; Celine,Wilke ^[4] ; Marie-Catherine,Vanderbeeken ^[5] ; Veronique,D'Hondt ^[1] ; Evandro,De Azambuja ^[1] ; Andrea,Gombos ^[1] ; Fabienne,Lebrun ^[1] ; Lissandra,Dal Lago ^[1] ; Fanny,Bustin ^[1] ; Marion,Maetens ^[1] ; Lieveke,Ameye ^[2] ; Isabelle,Veys ^[6] ; Stefan,Michiels ^[7] ; Marianne,Paesmans ^[8] ; Denis,Larsimont ^[4] ; Christos,Sotiriou ^[9] ; Jean-Marie,Nogaret ^[1] ; Martine,Piccart ^[2] ; Ahmad,Awada ^[7]

作者单位： Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ^[1] Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ^[2] Breast International Group (BIG aisbl), Brussels, Belgium. ^[3] Department of Radiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ^[4] Medigene AG, Planegg, Germany. ^[5] Department of Biostatistics, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ^[6] Department of Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ^[7] Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Univ. Paris-Sud, Villejuif, France. ^[8] Department of Pathology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. ^[9]